ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Infect Dis Ther,
  • DOI: 10.4172/2332-0877.1000546

Breaking the Resistance Barrier: A Mini-Review of the Advancements in Second-Line Treatments for HSV-1, HSV-2 and VZV Infections

Kimberly C Lince, Virgil K De Mario, Rachel Pittman and Rebecca L Sanchez*
Department of Applied Biomedical Sciences, University of the Incarnate Word School of Osteopathic Medicine, San Antonio, USA
*Corresponding Author : Rebecca L Sanchez, Department of Applied Biomedical Sciences, University Of The Incarnate Word School Of Osteopathic Medicine, San Antonio, USA, Email: rlsanche@uiwtx.edu

Received Date: Apr 28, 2023 / Published Date: May 29, 2023

Abstract

This mini-review aims to evaluate a systematic review of the available literature on the efficacy of second-line treatments for Herpes Simplex Viruses (HSV) that are resistant to first-line antiviral agents. The systematic review included a search of six databases for eligible manuscripts using terms related to antiviral resistance, herpes, and HSV. A total of 137 articles were included in qualitative synthesis, examining the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV. Of the included studies, 84.67% reported on HSV-1, with 34.31% of these studies reporting testing on resistant HSV strains. The following interventions were found to be effective as potential managements for resistant strains of HSV: nectin, amenamevir, methanol extract, monoclonal antibodies, arbidol, siRNA swarms, cucumis melo sulfated pectin, components from oleano europeae, griffithsin, morus alba L., nucleosides, botryosphaeran, monoterpenes, almond skin extracts, bortezomib, and flavonoid compounds. The available literature reviewed consistently supported the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Therefore, the review provided necessary information about treatment options for patients with resistant HSV infections, particularly those who are immunocompromised, and their providers.

Keywords: Infectious diseases; HSV; Drug resistance; Second-line treatment

Citation: Lince KC, Mario De VK, Pittman R, Sanchez RL (2023) Breaking the Resistance Barrier: A Mini-Review of the Advancements in Second-Line Treatments for HSV-1, HSV-2 and VZV Infections. J Infect Dis Ther 11:546. Doi: 10.4172/2332-0877.1000546

Copyright: © 2023 Lince KC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top